Literature DB >> 18724968

Serum total bilirubin level, prevalent stroke, and stroke outcomes: NHANES 1999-2004.

Todd S Perlstein1, Reena L Pande, Mark A Creager, Jennifer Weuve, Joshua A Beckman.   

Abstract

BACKGROUND: Bilirubin inhibits experimental atherosclerosis, is inversely associated with carotid plaque burden, and confers neuroprotection in experimental stroke. Clinical data addressing the association of bilirubin with stroke are not available. We hypothesized that higher bilirubin levels would be associated with reduced stroke prevalence and improved stroke outcomes.
METHODS: We used the National Health and Nutrition Examination Survey 1999 to 2004, a nationally representative cross-sectional examination of the United States civilian population, to examine the association of bilirubin with stroke. Of 13,214 adult participants with data on stroke history, serum total bilirubin level, and stroke risk factors, 453 reported a history of stroke. Of these, 138 participants reported an adverse stroke outcome, defined as a long-term health problem or disability due to stroke. We performed multivariable logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs) with adjustment for demographic characteristics and stroke risk factors.
RESULTS: After multivariable adjustment, a 1.71 micromol/L (0.1 mg/dL) increment in bilirubin level was associated with a 9% reduced odds of stroke (OR 0.91; 95% CI, 0.86-0.96) among all participants and with a 10% reduced odds of an adverse stroke outcome (OR 0.90; 95% CI, 0.80-1.00) among participants with a history of stroke.
CONCLUSIONS: These results suggest that a higher serum total bilirubin level is associated with reduced stroke prevalence and improved stroke outcomes. Our findings support the hypothesis that bilirubin may protect from stroke events and from neurologic damage in stroke.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18724968      PMCID: PMC2596911          DOI: 10.1016/j.amjmed.2008.03.045

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  27 in total

1.  Induction of heme oxygenase-1 inhibits the monocyte transmigration induced by mildly oxidized LDL.

Authors:  K Ishikawa; M Navab; N Leitinger; A M Fogelman; A J Lusis
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

2.  Reproducibility of blood markers of oxidative status and endothelial function in healthy individuals.

Authors:  Pascale G A Van Hoydonck; Evert G Schouten; Elisabeth H M Temme
Journal:  Clin Chem       Date:  2003-06       Impact factor: 8.327

3.  Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association.

Authors:  Thomas A Pearson; George A Mensah; R Wayne Alexander; Jeffrey L Anderson; Richard O Cannon; Michael Criqui; Yazid Y Fadl; Stephen P Fortmann; Yuling Hong; Gary L Myers; Nader Rifai; Sidney C Smith; Kathryn Taubert; Russell P Tracy; Frank Vinicor
Journal:  Circulation       Date:  2003-01-28       Impact factor: 29.690

4.  Serum bilirubin and risk of ischemic heart disease in middle-aged British men.

Authors:  L H Breimer; G Wannamethee; S Ebrahim; A G Shaper
Journal:  Clin Chem       Date:  1995-10       Impact factor: 8.327

5.  Bilirubin is an antioxidant of possible physiological importance.

Authors:  R Stocker; Y Yamamoto; A F McDonagh; A N Glazer; B N Ames
Journal:  Science       Date:  1987-02-27       Impact factor: 47.728

6.  Agreement between self-report of disease diagnoses and medical record validation in disabled older women: factors that modify agreement.

Authors:  Crystal F Simpson; Cynthia M Boyd; Michelle C Carlson; Michael E Griswold; Jack M Guralnik; Linda P Fried
Journal:  J Am Geriatr Soc       Date:  2004-01       Impact factor: 5.562

7.  Vascular heme oxygenase-1 induction suppresses microvascular thrombus formation in vivo.

Authors:  N Lindenblatt; R Bordel; W Schareck; M D Menger; B Vollmar
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-01-22       Impact factor: 8.311

Review 8.  Carbon monoxide and bile pigments: surprising mediators of vascular function.

Authors:  William Durante
Journal:  Vasc Med       Date:  2002-08       Impact factor: 3.239

9.  Bilirubin and ascorbate antioxidant activity in neonatal plasma.

Authors:  V Gopinathan; N J Miller; A D Milner; C A Rice-Evans
Journal:  FEBS Lett       Date:  1994-08-01       Impact factor: 4.124

10.  Antioxidation of human low density lipoprotein by unconjugated and conjugated bilirubins.

Authors:  T W Wu; K P Fung; J Wu; C C Yang; R D Weisel
Journal:  Biochem Pharmacol       Date:  1996-03-22       Impact factor: 5.858

View more
  57 in total

1.  Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CASTLE study.

Authors:  Cheryl McDonald; Jonathan Uy; Wenhua Hu; Victoria Wirtz; Salome Juethner; David Butcher; Donnie McGrath; Awny Farajallah; Graeme Moyle
Journal:  AIDS Patient Care STDS       Date:  2012-03-09       Impact factor: 5.078

2.  Relationship between total bilirubin and endothelial function, inflammation and oxidative stress in HIV-infected adults on stable antiretroviral therapy.

Authors:  Co Hileman; Ct Longenecker; Tl Carman; Gl Milne; D E Labbato; Nj Storer; Ca White; Ga McComsey
Journal:  HIV Med       Date:  2012-05-25       Impact factor: 3.180

3.  Subclinical change of liver function could also provide a clue on prognosis for patients with spontaneous intracerebral hemorrhage.

Authors:  Ge Tan; Zilong Hao; Chunyan Lei; Yanchao Chen; Ruozhen Yuan; Mangmang Xu; Ming Liu
Journal:  Neurol Sci       Date:  2016-07-08       Impact factor: 3.307

4.  Association Between Bilirubin, Atazanavir, and Cardiovascular Disease Events Among People Living With HIV Across the United States.

Authors:  Heidi M Crane; Robin M Nance; Susan R Heckbert; Corey Ritchings; Lisa Rosenblatt; Matthew Budoff; Brian R Wood; David L Tirschwell; H Nina Kim; William C Mathews; Elvin Geng; Richard D Moore; Peter W Hunt; Joseph J Eron; Greer A Burkholder; Daniel R Drozd; Felicia C Chow; Kyra J Becker; Joseph R Zunt; Emily L Ho; Rizwan Kalani; Andrew Huffer; Bridget M Whitney; Michael S Saag; Mari M Kitahata; Joseph A C Delaney
Journal:  J Acquir Immune Defic Syndr       Date:  2019-08-15       Impact factor: 3.731

5.  A review on laboratory liver function tests.

Authors:  Shivaraj Gowda; Prakash B Desai; Vinayak V Hull; Avinash A K Math; Sonal N Vernekar; Shruthi S Kulkarni
Journal:  Pan Afr Med J       Date:  2009-11-22

6.  Bilirubin Links Heme Metabolism to Neuroprotection by Scavenging Superoxide.

Authors:  Chirag Vasavda; Ruchita Kothari; Adarsha P Malla; Robert Tokhunts; Anthony Lin; Ming Ji; Cristina Ricco; Risheng Xu; Harry G Saavedra; Juan I Sbodio; Adele M Snowman; Lauren Albacarys; Lynda Hester; Thomas W Sedlak; Bindu D Paul; Solomon H Snyder
Journal:  Cell Chem Biol       Date:  2019-07-25       Impact factor: 8.116

7.  Atazanavir improves cardiometabolic measures but not vascular function in patients with long-standing type 1 diabetes mellitus.

Authors:  Jessica Milian; Allison B Goldfine; Jonah P Zuflacht; Caitlin Parmer; Joshua A Beckman
Journal:  Acta Diabetol       Date:  2015-01-08       Impact factor: 4.280

8.  Biliverdin protects against the deterioration of glucose tolerance in db/db mice.

Authors:  N Ikeda; T Inoguchi; N Sonoda; M Fujii; R Takei; E Hirata; H Yokomizo; J Zheng; Y Maeda; K Kobayashi; R Takayanagi
Journal:  Diabetologia       Date:  2011-05-26       Impact factor: 10.122

Review 9.  Bilirubin, a Cardiometabolic Signaling Molecule.

Authors:  Terry D Hinds; David E Stec
Journal:  Hypertension       Date:  2018-10       Impact factor: 10.190

10.  Antihypertensive actions of moderate hyperbilirubinemia: role of superoxide inhibition.

Authors:  David E Stec; Megan V Storm; Brandon E Pruett; Monette U Gousset
Journal:  Am J Hypertens       Date:  2013-03-12       Impact factor: 2.689

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.